SREBP is frequently upregulated in various cancers, potentially through tumor cell-expressed Programmed Cell Death Ligand 1, which activates the EGFR/integrin subunit β4/SREBP1c signaling axis, thereby driving lipid metabolic reprogramming and supporting tumor progression [22, 216]. This evidence concerns the gene EGFR and neoplasm.